Synergistic effect of regorafenib with aminoglycosides in ferroptosis-mediated liver injury.

ABSTRACT:

Background

Combination therapy of anticancer drugs with antibacterial agents has numerous advantages, but these may develop adverse drug events that were rarely studied. Specifically, regorafenib (REGO) mediates ferroptosis and causes liver injury when used in combination with aminoglycosides (AGs); however, this interaction remains unexplored.

Methodology

The study was conducted using both in vivo and in vitro assays involving Sprague-Dawley (SD) rats and HepG2/Huh7 to investigate ferroptosis-associated liver injury. The drugs REGO, amikacin (AMK), and gentamicin (GNT) were administered individually as well as in combination to evaluate their noxious effects on the liver. Subsequently, biochemical, histological, and transcriptomic analyses were carried out, an

SUBMITTER: Raja Dahar M 

PROVIDER: S-EPMC12303813 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature